These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 24997986)

  • 1. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.
    Li M; Zhang Z; Li X; Ye J; Wu X; Tan Z; Liu C; Shen B; Wang XA; Wu W; Zhou D; Zhang D; Wang T; Liu B; Qu K; Ding Q; Weng H; Ding Q; Mu J; Shu Y; Bao R; Cao Y; Chen P; Liu T; Jiang L; Hu Y; Dong P; Gu J; Lu W; Shi W; Lu J; Gong W; Tang Z; Zhang Y; Wang X; Chin YE; Weng X; Zhang H; Tang W; Zheng Y; He L; Wang H; Liu Y; Liu Y
    Nat Genet; 2014 Aug; 46(8):872-6. PubMed ID: 24997986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic
    Li M; Liu F; Zhang F; Zhou W; Jiang X; Yang Y; Qu K; Wang Y; Ma Q; Wang T; Bai L; Wang Z; Song X; Zhu Y; Yuan R; Gao Y; Liu Y; Jin Y; Li H; Xiang S; Ye Y; Zhang Y; Jiang L; Hu Y; Hao Y; Lu W; Chen S; Gu J; Zhou J; Gong W; Zhang Y; Wang X; Liu X; Liu C; Liu H; Liu Y; Liu Y
    Gut; 2019 Jun; 68(6):1024-1033. PubMed ID: 29954840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
    Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer.
    Iyer P; Shrikhande SV; Ranjan M; Joshi A; Gardi N; Prasad R; Dharavath B; Thorat R; Salunkhe S; Sahoo B; Chandrani P; Kore H; Mohanty B; Chaudhari V; Choughule A; Kawle D; Chaudhari P; Ingle A; Banavali S; Gera P; Ramadwar MR; Prabhash K; Barreto SG; Dutt S; Dutt A
    Int J Cancer; 2019 Apr; 144(8):2008-2019. PubMed ID: 30304546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
    Zhang Y; Zuo C; Liu L; Hu Y; Yang B; Qiu S; Li Y; Cao D; Ju Z; Ge J; Wang Q; Wang T; Bai L; Yang Y; Li G; Shao Z; Gao Y; Li Y; Bian R; Miao H; Li L; Li X; Jiang C; Yan S; Wang Z; Wang Z; Cui X; Huang W; Xiang D; Wang C; Li Q; Wu X; Gong W; Liu Y; Shao R; Liu F; Li M; Chen L; Liu Y
    J Hepatol; 2021 Nov; 75(5):1128-1141. PubMed ID: 34171432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ERBB pathway is recurrently mutated in gallbladder carcinoma.
    Cancer Discov; 2014 Sep; 4(9):OF12. PubMed ID: 25185194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stepwise correlation of TP53 mutations from pancreaticobiliary maljunction to gallbladder carcinoma: a retrospective study.
    Kawakami S; Takano S; Fukasawa M; Shindo H; Takahashi E; Fukasawa Y; Hayakawa H; Kuratomi N; Kadokura M; Hosomura N; Amemiya H; Kawaida H; Kono H; Maekawa S; Ichikawa D; Enomoto N
    BMC Cancer; 2021 Nov; 21(1):1245. PubMed ID: 34798839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-exome and targeted gene sequencing of large-cell lung carcinoma reveals recurrent mutations in the PI3K pathway.
    Guo JH; Ma YS; Lin JW; Jiang GX; He J; Lu HM; Wu W; Diao X; Fan QY; Wu CY; Liu JB; Fu D; Hou LK
    Br J Cancer; 2023 Aug; 129(2):366-373. PubMed ID: 37179440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
    Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
    Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Gene Sequencing of Gallbladder Carcinoma Identifies High-impact Somatic and Rare Germline Mutations.
    Yadav S; DE Sarkar N; Kumari N; Krishnani N; Kumar A; Mittal B
    Cancer Genomics Proteomics; 2017; 14(6):495-506. PubMed ID: 29109099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved.
    Mishra S; Kumari S; Srivastava P; Pandey A; Shukla S; Husain N
    Pathol Res Pract; 2022 Apr; 232():153806. PubMed ID: 35231860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.
    Lee SH; Kim JM; Lee DG; Lee J; Park JG; Han TS; Cho HS; Cho YL; Bae KH; Park YJ; Lee SJ; Lee MS; Huh YM; Jo DY; Yun HJ; Jeon HJ; Kim N; Joo M; Kim JS; Lee HJ; Min JK
    Cell Death Differ; 2021 Mar; 28(3):968-984. PubMed ID: 32989241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/β-catenin signaling pathway mutations.
    Yuan W; Zhang Z; Dai B; Wei Q; Liu J; Liu Y; Liu Y; He L; Zhou D
    Cancer; 2016 Jun; 122(11):1689-96. PubMed ID: 26998897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.
    Leone F; Cavalloni G; Pignochino Y; Sarotto I; Ferraris R; Piacibello W; Venesio T; Capussotti L; Risio M; Aglietta M
    Clin Cancer Res; 2006 Mar; 12(6):1680-5. PubMed ID: 16551849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p.
    Goeppert B; Truckenmueller F; Ori A; Fritz V; Albrecht T; Fraas A; Scherer D; Silos RG; Sticht C; Gretz N; Mehrabi A; Bewerunge-Hudler M; Pusch S; Bermejo JL; Dietrich P; Schirmacher P; Renner M; Roessler S
    Sci Rep; 2019 Mar; 9(1):4796. PubMed ID: 30886199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
    Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A
    Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer.
    Hirosawa T; Ishida M; Ishii K; Kanehara K; Kudo K; Ohnuma S; Kamei T; Motoi F; Naitoh T; Selaru FM; Unno M
    PLoS One; 2018; 13(11):e0206643. PubMed ID: 30395583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.
    Feng F; Cheng Q; Yang L; Zhang D; Ji S; Zhang Q; Lin Y; Li F; Xiong L; Liu C; Jiang X
    Oncotarget; 2017 Jan; 8(3):5349-5360. PubMed ID: 28029662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic landscape of gallbladder cancer: insights from whole exome sequencing.
    Awasthi S; Kumar R; Pradhan D; Rawal N; Goel H; Sahu P; Sisodiya S; Rana R; Kumar S; Dash NR; Das P; Agrawal U; Rath GK; Kaur T; Dhaliwal RS; Hussain S; Saluja SS; Tanwar P
    Int J Surg; 2024 Nov; 110(11):6883-6897. PubMed ID: 39166960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
    Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F
    Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.